BRPI0819912A2 - Composições para tratamento de uma condição inflamatória intestinal - Google Patents

Composições para tratamento de uma condição inflamatória intestinal

Info

Publication number
BRPI0819912A2
BRPI0819912A2 BRPI0819912-4A BRPI0819912A BRPI0819912A2 BR PI0819912 A2 BRPI0819912 A2 BR PI0819912A2 BR PI0819912 A BRPI0819912 A BR PI0819912A BR PI0819912 A2 BRPI0819912 A2 BR PI0819912A2
Authority
BR
Brazil
Prior art keywords
compositions
treating
inflammatory bowel
bowel condition
condition
Prior art date
Application number
BRPI0819912-4A
Other languages
English (en)
Inventor
Arnaud Fossat
Original Assignee
Txcell
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Txcell filed Critical Txcell
Publication of BRPI0819912A2 publication Critical patent/BRPI0819912A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/35—Allergens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/20—Cellular immunotherapy characterised by the effect or the function of the cells
    • A61K40/22—Immunosuppressive or immunotolerising
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/416—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/122—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells for inducing tolerance or supression of immune responses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/124—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells the cells being hematopoietic, bone marrow derived or blood cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Hematology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Mycology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Pulmonology (AREA)
  • Transplantation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
BRPI0819912-4A 2007-11-26 2008-11-26 Composições para tratamento de uma condição inflamatória intestinal BRPI0819912A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US99001307P 2007-11-26 2007-11-26
EP07301581A EP2062970A1 (en) 2007-11-26 2007-11-26 Compositions for treating an intestinal inflammatory condition
PCT/EP2008/066263 WO2009068575A1 (en) 2007-11-26 2008-11-26 Compositions for treating an intestinal inflammatory condition

Publications (1)

Publication Number Publication Date
BRPI0819912A2 true BRPI0819912A2 (pt) 2015-05-19

Family

ID=39201878

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0819912-4A BRPI0819912A2 (pt) 2007-11-26 2008-11-26 Composições para tratamento de uma condição inflamatória intestinal

Country Status (10)

Country Link
US (2) US8992907B2 (pt)
EP (2) EP2062970A1 (pt)
JP (2) JP5908670B2 (pt)
KR (2) KR20160013275A (pt)
CN (2) CN104721229A (pt)
AU (1) AU2008328805B2 (pt)
BR (1) BRPI0819912A2 (pt)
CA (1) CA2706429C (pt)
RU (1) RU2495121C2 (pt)
WO (1) WO2009068575A1 (pt)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2378287A1 (en) * 2010-04-15 2011-10-19 TXCell New method for isolating Tr1 cells
EP2439534A1 (en) * 2010-10-08 2012-04-11 TXCell Method for assessing the efficacy of a TR1 cell therapy in asubject
WO2012131419A1 (en) * 2011-03-25 2012-10-04 Txcell Method for using regulatory t cells in therapy
EP3969019A4 (en) 2019-05-14 2023-06-07 Hadasit Medical Research Services and Development Ltd. MILK-DERIVED EXTRACELLULAR VESICLES FOR USE IN THE TREATMENT OF INFLAMMATORY BOWEL DISEASE

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU3881100A (en) * 1999-03-15 2000-10-04 Human Genome Sciences, Inc. Human tumor necrosis factor receptor-like genes
US6746670B2 (en) * 2000-08-15 2004-06-08 Schering Corporation Regulatory T cells; methods
FR2824567B1 (fr) * 2001-05-11 2003-08-08 Inst Nat Sante Rech Med Procede d'obtention de lymphocytes tr1 regulateurs specifiques d'antigene
GB0307472D0 (en) * 2003-04-01 2003-05-07 Lorantis Ltd Medical treatment
FR2856700B1 (fr) 2003-06-24 2007-06-08 Txcell Procede d'identification de lymphocytes tr1 regulateurs par la presence et la surexpression de molecules specifiques et ses applications
EP1712615A1 (en) * 2005-04-15 2006-10-18 Txcell In vitro production of a cell population using feeder cells
PT1739166E (pt) * 2005-07-01 2011-09-22 Inst Nat Sante Rech Med Obtenção de células tr1 específicas para um auto-antigénio ou antigénio de alimentos a partir de uma população de pbmc ou de leucócito
SG165328A1 (en) 2005-08-31 2010-10-28 Ith Immune Therapy Holdings Ab Treatment of inflammatory bowel disease
DK2205721T3 (en) * 2007-10-17 2016-10-24 Txcell TR1 cells mesenchymal stem cells and uses thereof

Also Published As

Publication number Publication date
JP2015063550A (ja) 2015-04-09
CN104721229A (zh) 2015-06-24
CN101874108A (zh) 2010-10-27
RU2010126174A (ru) 2012-01-10
KR20160013275A (ko) 2016-02-03
EP2062970A1 (en) 2009-05-27
CA2706429A1 (en) 2009-06-04
CA2706429C (en) 2017-04-18
AU2008328805A1 (en) 2009-06-04
US8992907B2 (en) 2015-03-31
JP2011504482A (ja) 2011-02-10
KR20100098663A (ko) 2010-09-08
US20100303780A1 (en) 2010-12-02
JP5908670B2 (ja) 2016-04-26
AU2008328805B2 (en) 2015-02-12
WO2009068575A1 (en) 2009-06-04
EP2215217A1 (en) 2010-08-11
US20150157707A1 (en) 2015-06-11
RU2495121C2 (ru) 2013-10-10

Similar Documents

Publication Publication Date Title
DK2214679T3 (da) Kortikosteroidsammensætninger
BRPI0911998A2 (pt) métodos e kits para o tratamento de condições de desordem inflamatória intestinal
BRPI0911580A2 (pt) composições para o tratamento de uma condição artrítica
BRPI0909541A2 (pt) ''método para tratamento de doenças inflamatórias do cólon''
PT2185157T (pt) Composições de dhea para o tratamento da menopausa
GB2450974B (en) Treatment of inflammatory bowel disease with cannabinoids
BRPI1006229A2 (pt) composição incluindo uma quantidade suficiente de curcumina
BRPI0920276A2 (pt) várias composições para exclusão de exon dmd
BRPI0813725A2 (pt) Métodos e composições para tratamento de doenças
EP2167043A4 (en) NEW USE CO-CRYSTAL COMPOSITIONS
BRPI0816170A2 (pt) Composições poliolefínicas compatibilizadas
BRPI0820980A2 (pt) Composições e métodos para detecção de tiabs
ME01423B (me) Fungicidni sastavi
HUE059171T2 (hu) Kompozíciók
BRPI0811639A2 (pt) Cicloaquilaminas fenil substituídas como inibidores da recaptação de monoamina
DK2207429T3 (da) Lipidsammensætninger til behandling af gastro-intestinale sygdomme ogfremme af intestinal udvikling og modning
BR112012000762A2 (pt) enxerto de uma peça para bifurcação
BRPI1007600A2 (pt) composições e métodos para tratamento de doenças cardiovasculares
SI2289518T1 (sl) Terapevtsko sredstvo za vnetno črevesno bolezen
ZA201005735B (en) Methods and compositions for treating inflammatory bowel disease
BRPI0820885A2 (pt) Composições e métodos para diagnóstico precoce de gravidez
DK2107870T3 (da) Lavement med reduceret irritationseffekt til behandling af inflammatorisk tarmsygdom
PT2205720T (pt) Composições para tratamento de esclerose múltipla
PT2099446E (pt) Método de tratamento de doença inflamatória intestinal
SI2113254T1 (sl) Sestave za zdravljenje vnetnih avtoimunskih stanj

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B11B Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements